BIOMAT Database Logo BIOMAT Database Logo

Psychopharmacologic approaches to the borderline patient. 1988

S Zisook, and J E Ricketts
University of California, San Diego, La Jolla 92093.

Five case examples are presented to illustrate the role of psychopharmacology in the treatment of patients diagnosed as Borderline Personality Disorders. The cases range from organic through affective and schizophrenic syndromes which are not infrequently at the "border" of personality disorders, and which often respond to specific pharmacologic interventions. The importance of looking for and recognizing drug treatable syndromes within the wide array of patients who satisfy DSM-III criteria for Borderline Disorders is discussed.

UI MeSH Term Description Entries
D008094 Lithium An element in the alkali metals family. It has the atomic symbol Li, atomic number 3, and atomic weight [6.938; 6.997]. Salts of lithium are used in treating BIPOLAR DISORDER. Lithium-7,Lithium 7
D008152 Loxapine An antipsychotic agent used in SCHIZOPHRENIA. Loxapinsuccinate,Oxilapine,2-Chloro-11-(4-methyl-1-piperazinyl)-dibenz(b,f)(1,4)oxazepine,CL-71,563,Cloxazepine,Loxapine Hydrochloride,Loxapine Monohydrochloride,Loxapine Succinate,Loxipine Maleate,Loxipine Succinate,Loxitane,CL 71,563,CL71,563,Hydrochloride, Loxapine,Maleate, Loxipine,Succinate, Loxapine
D008996 Monoamine Oxidase Inhibitors A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414) MAO Inhibitor,MAO Inhibitors,Reversible Inhibitors of Monoamine Oxidase,Monoamine Oxidase Inhibitor,RIMA (Reversible Inhibitor of Monoamine Oxidase A),Reversible Inhibitor of Monoamine Oxidase,Inhibitor, MAO,Inhibitor, Monoamine Oxidase,Inhibitors, MAO,Inhibitors, Monoamine Oxidase
D010554 Personality Disorders A major deviation from normal patterns of behavior. Avoidant Personality Disorder,Impulse-Ridden Personality,Inadequate Personality,Avoidant Personality Disorders,Impulse Ridden Personality,Personality Disorder,Personality Disorder, Avoidant,Personality Disorders, Avoidant,Personality, Impulse-Ridden,Personality, Inadequate
D011619 Psychotropic Drugs A loosely defined grouping of drugs that have effects on psychological function. Here the psychotropic agents include the antidepressive agents, hallucinogens, and tranquilizing agents (including the antipsychotics and anti-anxiety agents). Psychoactive Agent,Psychoactive Agents,Psychoactive Drug,Psychopharmaceutical,Psychopharmaceuticals,Psychotropic Drug,Psychoactive Drugs,Agent, Psychoactive,Agents, Psychoactive,Drug, Psychoactive,Drug, Psychotropic,Drugs, Psychoactive,Drugs, Psychotropic
D001883 Borderline Personality Disorder A personality disorder marked by a pattern of instability of interpersonal relationships, self-image, and affects, and marked impulsivity beginning by early adulthood and present in a variety of contexts. (DSM-IV) Personality Disorder, Borderline,Disorder, Borderline Personality,Borderline Personality Disorders,Disorders, Borderline Personality,Personality Disorders, Borderline
D002746 Chlorpromazine The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. Aminazine,Chlorazine,Chlordelazine,Chlorpromazine Hydrochloride,Contomin,Fenactil,Largactil,Propaphenin,Thorazine,Hydrochloride, Chlorpromazine
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

S Zisook, and J E Ricketts
Psychopharmacologic approaches to borderline syndromes.
January 1984, Comprehensive psychiatry,
S Zisook, and J E Ricketts
[Psychopharmacologic approaches to schizophrenic psychoses].
June 1995, L'Encephale,
S Zisook, and J E Ricketts
Psychopharmacologic treatment of borderline personality disorder.
June 2013, Dialogues in clinical neuroscience,
S Zisook, and J E Ricketts
Psychopharmacologic and behavioral approaches to chronic arthritic pain.
August 1984, Comprehensive therapy,
S Zisook, and J E Ricketts
Psychopharmacologic approach to the medically ill patient.
December 1984, The Psychiatric clinics of North America,
S Zisook, and J E Ricketts
Psychopharmacologic management of patients with borderline personality disorder.
June 1988, Canadian journal of psychiatry. Revue canadienne de psychiatrie,
S Zisook, and J E Ricketts
[Seasonal depression. Phototherapy and psychopharmacologic approaches].
October 1992, Medizinische Monatsschrift fur Pharmazeuten,
S Zisook, and J E Ricketts
Psychopharmacologic therapy and the ambulatory patient.
January 1966, Psychosomatics,
S Zisook, and J E Ricketts
Current approaches to the psychopharmacologic treatment of depression in children and adolescents.
January 1996, Journal of child and adolescent psychiatric nursing : official publication of the Association of Child and Adolescent Psychiatric Nurses, Inc,
S Zisook, and J E Ricketts
Psychopharmacologic approaches to therapy for chest pain of presumed esophageal origin.
May 1992, The American journal of medicine,
Copied contents to your clipboard!